Retrospective evaluation of caspofungin therapy in invasive aspergillosis (RECAM-IA)
| Autor: | Nikolay Klimko, Ritesh N. Kumar, Sasisopin Kiertiburanakul, Tami Wisniewski, Michel Laverdière, Kliasova Ga, Rudolf Trenschel |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Antifungal
medicine.medical_specialty business.industry medicine.drug_class Retrospective cohort study Dermatology General Medicine bacterial infections and mycoses Aspergillosis medicine.disease chemistry.chemical_compound Infectious Diseases chemistry Refractory Internal medicine Anesthesia medicine Therapy duration Caspofungin Adverse effect business Survival analysis |
| Zdroj: | Mycoses. 54:e148-e153 |
| ISSN: | 0933-7407 |
| Popis: | To evaluate caspofungin in high-risk invasive aspergillosis (IA) patient, a retrospective review of patient characteristics, antifungal therapies and clinical outcomes on hospitalised patients at sites in Russia, Canada, Germany, and Thailand was performed. Fifty-five patients were included, six with proven and 49 with probable aspergillosis; 76.4% had haematological diseases, 80% were on immunosuppressive drugs, 32.7% were neutropenic at caspofungin initiation. Median duration of prior antifungal therapy was 9 days (range 1-232). Reasons for initiating caspofungin included: disease refractory to first-line antifungal (49.1%) and toxicities with prior antifungals (18.2%). Median caspofungin therapy duration was 14 days (range 2-62), with a median of 13 days (range 1-62) as monotherapy. Favourable responses were observed in 45.5% of the patients, complete responses in 40% and partial responses in 5.5%; 74.5% survived 7 days after completion of caspofungin therapy with 69.1% having been successfully discharged from the hospital. Few patients (14.6%) on caspofungin switched because of suspected resistance, lack of response or adverse events. There were no increases in hospital stay as a result of adverse events or drug-drug interactions related to caspofungin; 7.3% of patients had a mean value of 13 (± 14.11) days of increased stay attributable to treatment failure. Caspofungin was well-tolerated. It exhibited effectiveness and high survival in treating severe IA patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text